Aspergillosis in Chronic Granulomatous Disease

Jill King, Stefanie S. V. Henriet, Adilia Warris

Research output: Contribution to journalArticle

11 Citations (Scopus)
6 Downloads (Pure)

Abstract

Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections by Aspergillus species remain the single most common infectious cause of death in CGD. Recent developments in curative treatment options, such as haematopoietic stem cell transplantation, will change the prevalence of infectious complications including invasive aspergillosis in CGD patients. However, invasive aspergillosis in a previously healthy host is often the first presenting feature of this primary immunodeficiency. Recognizing the characteristic clinical presentation and understanding how to diagnose and treat invasive aspergillosis in CGD is of utmost relevance to improve clinical outcomes. Significant differences exist in fungal epidemiology, clinical signs and symptoms, and the usefulness of non-culture based diagnostic tools between the CGD host and neutropenic patients, reflecting underlying differences in the pathogenesis of invasive aspergillosis shaped by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase deficiency.
Original languageEnglish
Article number15
Pages (from-to)1-16
Number of pages16
JournalJournal of Fungi
Volume2
Issue number2
DOIs
Publication statusPublished - 26 May 2016

Fingerprint

Chronic Granulomatous Disease
Aspergillosis
Hematopoietic Stem Cell Transplantation
Aspergillus
NADP
Signs and Symptoms
Cause of Death
Oxidoreductases
Epidemiology
Incidence
Infection

Keywords

  • aspergillosis
  • chronic granulomatous disease
  • Aspergillus fumigatus
  • Aspergillus nidulans
  • NADPH-oxidase
  • respiratory burst

Cite this

King, J., Henriet, S. S. V., & Warris, A. (2016). Aspergillosis in Chronic Granulomatous Disease. Journal of Fungi, 2(2), 1-16. [15]. https://doi.org/10.3390/jof2020015

Aspergillosis in Chronic Granulomatous Disease. / King, Jill; Henriet, Stefanie S. V.; Warris, Adilia.

In: Journal of Fungi, Vol. 2, No. 2, 15, 26.05.2016, p. 1-16.

Research output: Contribution to journalArticle

King, J, Henriet, SSV & Warris, A 2016, 'Aspergillosis in Chronic Granulomatous Disease', Journal of Fungi, vol. 2, no. 2, 15, pp. 1-16. https://doi.org/10.3390/jof2020015
King, Jill ; Henriet, Stefanie S. V. ; Warris, Adilia. / Aspergillosis in Chronic Granulomatous Disease. In: Journal of Fungi. 2016 ; Vol. 2, No. 2. pp. 1-16.
@article{7f4f6d7a539b4ba9bb8e1684a3d88434,
title = "Aspergillosis in Chronic Granulomatous Disease",
abstract = "Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections by Aspergillus species remain the single most common infectious cause of death in CGD. Recent developments in curative treatment options, such as haematopoietic stem cell transplantation, will change the prevalence of infectious complications including invasive aspergillosis in CGD patients. However, invasive aspergillosis in a previously healthy host is often the first presenting feature of this primary immunodeficiency. Recognizing the characteristic clinical presentation and understanding how to diagnose and treat invasive aspergillosis in CGD is of utmost relevance to improve clinical outcomes. Significant differences exist in fungal epidemiology, clinical signs and symptoms, and the usefulness of non-culture based diagnostic tools between the CGD host and neutropenic patients, reflecting underlying differences in the pathogenesis of invasive aspergillosis shaped by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase deficiency.",
keywords = "aspergillosis, chronic granulomatous disease, Aspergillus fumigatus, Aspergillus nidulans, NADPH-oxidase, respiratory burst",
author = "Jill King and Henriet, {Stefanie S. V.} and Adilia Warris",
note = "Acknowledgments: This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377 to Jill King and Adilia Warris.",
year = "2016",
month = "5",
day = "26",
doi = "10.3390/jof2020015",
language = "English",
volume = "2",
pages = "1--16",
journal = "Journal of Fungi",
issn = "2309-608X",
publisher = "MDPI",
number = "2",

}

TY - JOUR

T1 - Aspergillosis in Chronic Granulomatous Disease

AU - King, Jill

AU - Henriet, Stefanie S. V.

AU - Warris, Adilia

N1 - Acknowledgments: This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377 to Jill King and Adilia Warris.

PY - 2016/5/26

Y1 - 2016/5/26

N2 - Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections by Aspergillus species remain the single most common infectious cause of death in CGD. Recent developments in curative treatment options, such as haematopoietic stem cell transplantation, will change the prevalence of infectious complications including invasive aspergillosis in CGD patients. However, invasive aspergillosis in a previously healthy host is often the first presenting feature of this primary immunodeficiency. Recognizing the characteristic clinical presentation and understanding how to diagnose and treat invasive aspergillosis in CGD is of utmost relevance to improve clinical outcomes. Significant differences exist in fungal epidemiology, clinical signs and symptoms, and the usefulness of non-culture based diagnostic tools between the CGD host and neutropenic patients, reflecting underlying differences in the pathogenesis of invasive aspergillosis shaped by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase deficiency.

AB - Patients with chronic granulomatous disease (CGD) have the highest life-time incidence of invasive aspergillosis and despite the availability of antifungal prophylaxis, infections by Aspergillus species remain the single most common infectious cause of death in CGD. Recent developments in curative treatment options, such as haematopoietic stem cell transplantation, will change the prevalence of infectious complications including invasive aspergillosis in CGD patients. However, invasive aspergillosis in a previously healthy host is often the first presenting feature of this primary immunodeficiency. Recognizing the characteristic clinical presentation and understanding how to diagnose and treat invasive aspergillosis in CGD is of utmost relevance to improve clinical outcomes. Significant differences exist in fungal epidemiology, clinical signs and symptoms, and the usefulness of non-culture based diagnostic tools between the CGD host and neutropenic patients, reflecting underlying differences in the pathogenesis of invasive aspergillosis shaped by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase deficiency.

KW - aspergillosis

KW - chronic granulomatous disease

KW - Aspergillus fumigatus

KW - Aspergillus nidulans

KW - NADPH-oxidase

KW - respiratory burst

U2 - 10.3390/jof2020015

DO - 10.3390/jof2020015

M3 - Article

VL - 2

SP - 1

EP - 16

JO - Journal of Fungi

JF - Journal of Fungi

SN - 2309-608X

IS - 2

M1 - 15

ER -